MB and Sepsis: While the present trial focuses on dampening chronic inflammation in dialysis patients, the results also suggest MCO-Ci dialysis as a treatment option for other disease entities demanding removal of solutes in this molecular size range such as free light chains, myoglobin, and cytokines in sepsis.